Latest Breaking News On - University of helsinki immunovirotherapy - Page 1 : comparemela.com

Valo Therapeutics Acquires University of Helsinki s PeptiBAC Cancer and Infectious Disease Vaccination Technology Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy News provided by Share this article Share this article HELSINKI, April 19, 2021 /PRNewswire/ Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary PeptiBAC technology from the University of Helsinki, Finland. PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in cancer. The BGC vaccine, one of the earliest immunotherapies, has been widely used globa

Eteläuomen läiVincenzo cerulloMatthew vaughanPaul highamPrnewswire valo therapeutics limited txUniversity of helsinkiHelsinki innovation services ltdUnited nations sustainable development goalsScius communications for valoUniversity of helsinki immunovirotherapyTherapeutics limitedBacillus calmette guProfessor vincenzo cerulloInnovation services ltdUnited nations sustainable developmentவின்சென்சோ சிஇஆர்யுவ்எல்எல்ஓ